Rolling circle replication

Boundless Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, December 28, 2022
Biotechnology, Health, Science, Research, Oncology, Rolling circle replication, Conference, DNA, Bio, Therapy, Pharmaceutical industry

Boundless Bio .

Key Points: 
  • Boundless Bio .
  • a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will present at the 41st Annual J.P. Morgan Healthcare Conference which will take place in San Francisco.
  • Presentation details are as follows:

Boundless Bio to Participate at Two Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 15, 2022
Science, Biotechnology, Research, Pharmaceutical, Optical, Public Relations, Investor Relations, Health, Communications, Therapy, Rolling circle replication, Bio, DNA, Patient

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will participate in a presentation and fireside chat at upcoming investor conferences:

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that its Chief Executive Officer, Zachary Hornby, will participate in a presentation and fireside chat at upcoming investor conferences:
    Boundless Bio is a next-generation precision oncology company dedicated to the discovery and development of a new class of drugs targeting a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20221115005046/en/

SOPHiA GENETICS Unveils Strategy to Drive Health Care Innovations at Inaugural Investor Day Event

Retrieved on: 
Wednesday, September 21, 2022
Sophia, Therapy, Acceleration, Algorithm, Investor relations, Twitter, Machine learning, Entrepreneurship, Research, Neoplasm, U.S. Securities and Exchange Commission, Oncogene, LinkedIn, Sophia Genetics, Company, Health, ECHO, Partnership, Immunotherapy, IVD, Forward-looking statement, Patient, Intelligence, Memorial Sloan Kettering Cancer Center, Cancer, CEO, Arbutus Biopharma, Technology, Instagram, Solution, Rolling circle replication, Drug development, MSK, GENETICS, DNA, Hospital, Multimedia, Precision medicine, Mobile phone, Medical device, Management, Medical imaging, Facebook

BOSTON and GENEVA, Sept. 21, 2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, hosted its first-ever Investor Day on Tuesday, September 20, 2022, in New York City.

Key Points: 
  • One takeaway from the event was SOPHiA GENETICS' acceleration into the Biopharma space, which opens the door for new opportunities for market growth.
  • SOPHiA GENETICS recently announced a memorandum of understanding to enter into a collaboration with Memorial Sloan Kettering Cancer Center ("MSK").
  • The collaboration agreements will also allow SOPHiA GENETICS' global network of healthcare providers access to MSK's proprietary tumor sequencing tests such as MSK-IMPACT , for analyzing tumors.
  • "Our vision is to expand access to world-class data, including to our current network, which contributes to the collective intelligence of the SOPHiA GENETICS platform," said Philippe Menu, M.D.-Ph.D., Chief Medical Officer, SOPHiA GENETICS.

SOPHiA GENETICS Unveils Strategy to Drive Health Care Innovations at Inaugural Investor Day Event

Retrieved on: 
Wednesday, September 21, 2022
Sophia, Therapy, Acceleration, Algorithm, Investor relations, Twitter, Machine learning, Entrepreneurship, Research, Neoplasm, U.S. Securities and Exchange Commission, Oncogene, LinkedIn, Sophia Genetics, Health, ECHO, Partnership, Immunotherapy, IVD, Forward-looking statement, Vision, Intelligence, Memorial Sloan Kettering Cancer Center, Patient, Cancer, CEO, Technology, Instagram, Boundless, Solution, Sutro Biopharma, Rolling circle replication, Drug development, GENETICS, DNA, GLOBE, Hospital, Precision medicine, Mobile phone, Medical device, Medical imaging, Facebook

BOSTON and GENEVA, Switzerland, Sept. 21, 2022 (GLOBE NEWSWIRE) -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space, hosted its first-ever Investor Day on Tuesday, September 20, 2022, in New York City.

Key Points: 
  • One takeaway from the event was SOPHiA GENETICS acceleration into the Biopharma space, which opens the door for new opportunities for market growth.
  • SOPHiA GENETICS recently announced a memorandum of understanding to enter into a collaboration with Memorial Sloan Kettering Cancer Center (MSK).
  • The collaboration agreements will also allow SOPHiA GENETICS global network of healthcare providers access to MSKs proprietary tumor sequencing tests such as MSK-IMPACT , for analyzing tumors.
  • Our vision is to expand access to world-class data, including to our current network, which contributes to the collective intelligence of the SOPHiA GENETICS platform, said Philippe Menu, M.D.-Ph.D., Chief Medical Officer, SOPHiA GENETICS.

Cancer Grand Challenges Celebrates New Teams Joining World-Class Scientific Community

Retrieved on: 
Thursday, June 16, 2022
Research, Genetics, Stem Cells, Philanthropy, Biotechnology, Health, Fund Raising, Science, Oncology, Time, Heart, Freedom, University College London, Cachexia, CRUK, Tumor microenvironment, Institute, Sarcoma, University of California, Research, Nursing, Knowledge, Weill Cornell Medicine, Rutgers Cancer Institute of New Jersey, Stanford University School of Medicine, National, Grand Challenges, Â, Disease, DNA, University, Eppley Institute for Research in Cancer and Allied Diseases, Health, Cold Spring Harbor Laboratory, Quality of life, Rolling circle replication, Development, International Agency for Research on Cancer, Survival, Organic, NCI, Cancer Research UK, Patient, Neoplasm, Thought, Diagnosis, Cell, Brain, Geography, National Cancer Institute, Pharmaceutical industry, Dietary supplement, Medical imaging, Renewable energy, Cancer

At its core, Cancer Grand Challenges provides multidisciplinary teams the time, space and freedom to innovate and drive progress against cancer that the world urgently needs.

Key Points: 
  • At its core, Cancer Grand Challenges provides multidisciplinary teams the time, space and freedom to innovate and drive progress against cancer that the world urgently needs.
  • Along with its founding partners, the National Cancer Institute and Cancer Research UK, Cancer Grand Challenges leverages support from partners across the globe who share the same vision to fuel scientific discovery through collaboration.
  • The four new Cancer Grand Challenges teams add to a growing community of investigators daring to take on cancers toughest challenges now 700+ researchers, advocates and partners across 10 countries and 68 research institutions.
  • Co-founded in 2020 by two of the largest funders of cancer research in the world, Cancer Research UK and the National Cancer Institute, Cancer Grand Challenges supports a global community of diverse, world-class research teams to come together, think differently and take on some of cancers toughest challenges.

Team Led by Boundless Bio Scientific Founders Receives $25M Award to Better Understand Extrachromosomal DNA (ecDNA) Through Cancer Grand Challenges

Retrieved on: 
Thursday, June 16, 2022
Oncology, Health, Genetics, Research, Science, Biotechnology, EGFR, Cancer, Department, Therapy, University of California, San Diego, Oncogene, Chemical biology, CRUK, Boundless, National, Biology, Scripps Research, Research, Survival, Computer science and engineering, Bio, Recurrence, Growth, DNA, Jackson Laboratory, Computational biology, University, Professor, News, Stanford University, Rolling circle replication, Associate, Radiation, Cancer Research UK, NCI, Patient, Chromosome, Florine, Computer science, Genomics, National Cancer Institute, Glioblastoma, Cell division, Immunotherapy, Dietary supplement, Management, Pharmaceutical industry, Sales, Genetics

has been awarded $25 million in funding by the National Cancer Institute (NCI*) and Cancer Research UK (CRUK) through Cancer Grand Challenges to deepen the understanding of the role of ecDNA in cancer pathogenesis.

Key Points: 
  • has been awarded $25 million in funding by the National Cancer Institute (NCI*) and Cancer Research UK (CRUK) through Cancer Grand Challenges to deepen the understanding of the role of ecDNA in cancer pathogenesis.
  • We at Boundless continue to be inspired by Dr. Mischel and the eDyNAmiC scientific teams commitment to advancing the scientific understanding of ecDNA.
  • Extrachromosomal DNA (ecDNA) are circular units of nuclear DNA that are physically distinct from chromosomes and are found within cancer cells.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.

Boundless Bio to Present at the 2022 Jefferies Healthcare Conference

Retrieved on: 
Monday, June 6, 2022
Biotechnology, Health, Oncology, Bio, Patient, DNA, Conference, Rolling circle replication, Therapy, Medical imaging

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that Chief Executive Officer, Zachary Hornby, will present at the 2022 Jefferies Healthcare Conference, which will take place in New York City.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that Chief Executive Officer, Zachary Hornby, will present at the 2022 Jefferies Healthcare Conference, which will take place in New York City.
  • Presentation details are as follows:
    Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005217/en/

Boundless Bio Appoints Sara Weymer as Vice President, Clinical Operations

Retrieved on: 
Friday, June 3, 2022
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Destiny, Cornell University, NK, Organization, Therapy, Bio, Patient, DNA, Trial of the century, IPSC, Rolling circle replication, Parexel, Biogen, IND World's Fair Line, Drug development, Pharmaceutical industry, Medical imaging

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that Ms. Sara Weymer has been appointed as Vice President of Clinical Operations.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced that Ms. Sara Weymer has been appointed as Vice President of Clinical Operations.
  • Sara brings significant experience in planning and executing clinical trials in oncology and will be tremendously valuable as we seek to establish clinical proof of concept of ecDTx.
  • Sara Weymer has over 20 years of experience in clinical research and drug development.
  • I am thrilled to join Boundless Bio as the company makes preparations for the clinic, said Ms. Weymer.

Boundless Bio Presents Data on the Novel Discovery of the Association Between Extrachromosomal DNA (ecDNA) and Replication Stress at the American Association for Cancer Research Annual Meeting 2022

Retrieved on: 
Friday, April 8, 2022
Oncology, Health, Genetics, Research, Science, Biotechnology, Bio, Cancer, Genome, Therapy, PM, DNA, DNA repair, Oncogene, AACR, Rolling circle replication, American Association, Poster, Association, American Association for Cancer Research, Science, Patient, Medical imaging

This study demonstrates ecDNA-enabled gene amplified cancers have inherently high replication stress, thereby providing a unique point of intervention for our novel ecDNA-directed therapeutics (ecDTx).

Key Points: 
  • This study demonstrates ecDNA-enabled gene amplified cancers have inherently high replication stress, thereby providing a unique point of intervention for our novel ecDNA-directed therapeutics (ecDTx).
  • While the drivers of replication stress remain unclear, excessive replication stress leads to extensive DNA damage and cancer cell death.
  • The results demonstrate ecDNA-enabled colorectal cancer cells have intrinsically elevated levels of replication stress and are hypersensitive to replication stress inducing agents.
  • These novel findings highlight replication stress as a potential synthetic lethal approach in ecDNA amplified cancers.

Boundless Bio Announces Upcoming Presentation at the American Association for Cancer Research Annual Meeting 2022

Retrieved on: 
Wednesday, March 9, 2022
Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, AACR, American Association for Cancer Research, Therapy, Survival, Oncogene, Cancer, Association, Chromosome, DNA, Rolling circle replication, Radiation, Patient, American Association, Bio, Cell division, Immunotherapy, Growth, Neoplasm, Recurrence, Medical imaging, Vaccine, ecDNA, Boundless Bio, ECDNA, BOUNDLESS BIO

Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced plans to present at the American Association for Cancer Research (AACR) Annual Meeting 2022, held in New Orleans and virtually from April 8-13, 2022.

Key Points: 
  • Boundless Bio , a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in oncogene amplified cancers, today announced plans to present at the American Association for Cancer Research (AACR) Annual Meeting 2022, held in New Orleans and virtually from April 8-13, 2022.
  • The in-person poster presentation reveals a novel association between ecDNA bearing tumors and high replication stress, presenting a potential therapeutic strategy for ecDNA-enabled oncogene amplified cancers.
  • ecDNA replicate within cancer cells and, due to their lack of centromeres, can be asymmetrically passed to daughter cells during cell division, leading to focal gene amplification and copy number heterogeneity in cancer.
  • Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with oncogene amplified cancers.